Obsidian Therapeutics (NASDAQ:OBX) Coverage Initiated at Leerink Partners

Stock analysts at Leerink Partners began coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage set an “outperform” rating and a $32.00 price target on the stock. Leerink Partners’ price target suggests a potential upside of 84.65% from the company’s previous close.

Several other research analysts have also recently issued reports on the stock. William Blair initiated coverage on shares of Obsidian Therapeutics in a report on Wednesday, September 9th. They issued an “outperform” rating for the company. Wall Street Zen upgraded shares of Obsidian Therapeutics to a “sell” rating in a report on Saturday. TD Cowen started coverage on Obsidian Therapeutics in a research note on Thursday, August 6th. They set a “buy” rating on the stock. Piper Sandler initiated coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target for the company. Finally, Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Obsidian Therapeutics Stock Performance

OBX opened at $17.33 on Tuesday. Obsidian Therapeutics has a 1 year low of $14.57 and a 1 year high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.